Items Tagged ‘trastuzumab. her2’

July 27th, 2016

Neratinib Improves Cancer-Free Survival in Early Breast Cancer


The targeted agent neratinib (PB272), which is still in clinical trials, demonstrated an improvement in cancer-free survival when used after Herceptin® (trastuzumab) in early-stage, HER2-positive breast cancer. Approximately 20-30% of breast cancer is referred to as human epidermal growth factor receptor-2 (HER2)-positive.  This means that the breast cancer cells have too many HER2 proteins on […]

View full entry

Tags: Breast Cancer, early breast cancer, exteNET, HER2-positive, herceptin, neratinib, News, Stage I Node Negative Breast Cancer, Stages II-III Breast Cancer, trastuzumab. her2